Is Wegovy Safer Than Mounjaro, or Is It the Other Way Around?

The decision you're really making, and what 'safer' means here

When people ask whether Wegovy is safer than Mounjaro, they usually mean one of three things: which has the more tolerable side-effect profile, which carries fewer serious risks, or which is better studied. The honest answer to each is more nuanced than a simple ranking.

Mounjaro (tirzepatide) activates both the GLP-1 and GIP receptors. Wegovy (semaglutide) activates GLP-1 only. Both slow gastric emptying and reduce appetite; both share a GI-led side-effect profile; and both carry a Black Triangle (▼) in the UK, meaning the MHRA requires additional monitoring while longer-term data accumulates. That shared symbol matters: neither medicine has a clean bill of health that the other lacks.

If you want a quick self-check before reading further, the most common question our prescribers hear is whether one medicine is 'gentler'. The body-of-evidence answer is below.

The side-by-side detail between the two medicines covers results as well as tolerability. Here the focus is on safety specifically.

Side effects, where the profiles differ and where they overlap

The overlap is large. Nausea, loose stools, constipation, reflux and fatigue appear in the trial data for both medicines, and both tend to be most noticeable in the early weeks of a dose increase, then settle. The NHS medicines page for tirzepatide and the NHS page for semaglutide both list injection-site reactions, headache and dizziness alongside those GI effects.

One clinically meaningful difference: tirzepatide's additional action on GIP receptors means the tolerability impact of reduced pill absorption deserves attention. UK guidance advises women on oral contraceptives to use a non-oral method (such as condoms) for the first four weeks of tirzepatide treatment and for four weeks after each dose increase. The same caution also applies to HRT taken as tablets; NHS England advises discussing a switch to transdermal patches or gel. There is no equivalent recommendation for semaglutide.

On pancreatitis, the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious risk across GLP-1 medicines as a class, not singling out either product over the other. Severe, persistent stomach pain reaching towards the back is the warning sign; seek urgent medical help if that happens.

If you are weighing up which is safer, semaglutide or tirzepatide, that comparison explores the mechanism differences behind these profiles in more depth.

What the head-to-head trial and NICE both say

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) noted that indirect comparisons favour tirzepatide on efficacy. Neither the trial nor NICE concluded that one was safer in the sense of fewer serious adverse events.

For a structured comparison, the figures below are drawn from the respective trial programmes and UK regulatory documentation:

For more on results rather than safety, the Mounjaro-versus-Wegovy results page covers the efficacy data in detail.

How the prescriber makes the call, and how to check any pharmacy is legitimate

Choosing between these two medicines is not a self-service exercise. Your prescriber weighs your full picture: current medications, any history of pancreatitis or gallbladder problems, whether you use oral contraception or HRT, your BMI and the weight-related conditions behind it. Someone managing type 2 diabetes alongside obesity, for instance, will have a different conversation from someone whose sole indication is BMI.

People sometimes also ask whether Mounjaro is safer than Ozempic, particularly if they have seen both mentioned online, and that page works through the evidence in the same structured way. Separately, if you are already on tirzepatide and wondering about switching from Mounjaro to Wegovy, there are practical and clinical factors your prescriber will want to discuss before any change is made.

If you are considering treatment from any online pharmacy, spend thirty seconds confirming it appears on the GPhC pharmacy register before submitting anything personal. Fake pens have been seized in large quantities across the UK, and sellers offering these medicines without a prescription are a serious risk, not a bargain.

At nume, our clinical team reviews every consultation, same day, by a named prescriber, and if you want to read more about whether semaglutide is safer than tirzepatide before that conversation, that page sets out the evidence clearly. If tirzepatide and semaglutide both fit your profile on paper, that conversation will help you understand which is the more practical choice given your lifestyle and any medicines you already take. Speak to our prescribers to start that assessment.